Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07390422 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Duodenal pulsENDO for Suboptimally Controlled Type II Diabetes Mellitus and Steatotic Liver Disease

Study acronym: DRESS-1
StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

  1. Recruitment opened Eligibility criteria expanded, about 24 words · Site details revised Show 2 more changesShow less
    • Eligibility criteria expanded, about 24 words
    • Site details revised
  2. Study description revisedv3 See this version in full on ClinicalTrials.gov ↗
  3. Start date: Apr 1, 2026 to Sep 1, 2026 Primary completion pushed from Mar 31, 2031 to Aug 30, 2031 · Completion pushed from Mar 31, 2033 to Aug 30, 2033 · Interventions: ReCET treatment (Procedure) to pulsENDO treatment (Procedure) · 3 morev2 Show 6 more changesShow less
    • Primary completion pushed from Mar 31, 2031 to Aug 30, 2031
    • Completion pushed from Mar 31, 2033 to Aug 30, 2033
    • Interventions: ReCET treatment (Procedure) to pulsENDO treatment (Procedure)
    • Eligibility criteria revised
    • Study description revised
    • Study title revised

    See this version in full on ClinicalTrials.gov ↗

  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study is designed to evaluate the efficacy, safety, and mechanisms of pulsENDO procedure in patients with T2DM and its effect on MASLD.
Trial Details
NCT Number NCT07390422
Lead Sponsor Chinese University of Hong Kong
Conditions T2DM (Type 2 Diabetes Mellitus), MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, Metabolic Syndrome (MetS)
Enrollment 40 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov